Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial

By sjmartinez • August 22, 2023

John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. PMID: 37236398.

Tags: Adjuvant, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, safety

Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Duivon M, Christy F, Thomas E, Lequesne J, Castel H, Gaudin C, Delmas D, Boyault S, Rigal O, Bousrih C, Lévy C, Lerebours F, Di[...]

Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply

Bardia A, Schwaederle M, Curigliano G. Trastuzumab Deruxtecan in Low or Ultralow HER2 Metastatic Breast Cancer. Reply. N Engl J Med. 2025 Feb 20;392(8):830-831. doi:[...]

Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity?

Sedrak MS, Asnani A. Frailty: Can a Biological Aging Marker Enhance Precision Risk Assessment of Cancer Therapy Cardiotoxicity? JACC CardioOncol. 2025 Feb;7(2):122-124. doi: 10.1016/j.jaccao.2025.01.004. PMID:[...]